Press Releases

Nexeon MedSystems Announces First Quarter 2018 Financial Results

[fa icon="calendar"] May 22, 2018 - by : Company News

Company News

Nexeon MedSystems Announces First Quarter 2018 Financial Results

Dallas, TX, May 21, 2018 -- Nexeon MedSystems Inc (”Nexeon”) (OTCQB: NXNN) a neurostimulation medical device company, announced today financial results for the first quarter ended March 31, 2018.

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 0 Comments

Nexeon MedSystems Appoints Wes Dittmer, CPA to Board of Directors

[fa icon="calendar"] April 27, 2018 - by : Company News

Company News

DALLAS, April 25, 2018 -- Nexeon MedSystems Inc (“Nexeon”) (OTCQB:NXNN) a neurostimulation medical device company, today announced the appointment of Wes Dittmer to the Company’s Board of Directors, effective April 24, 2018. Mr. Dittmer has been appointed Chairman of the Company’s Audit Committee and a member of the Nominating and Governance Committee and Compensation Committee.

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 0 Comments

Nexeon MedSystems Announces Fourth Quarter and Full Year Results

[fa icon="calendar"] April 5, 2018 - by : Company News

Company News

DALLAS, April 05, 2018 (GLOBE NEWSWIRE) -- Nexeon MedSystems Inc (”Nexeon”) (OTCQB:NXNN) a neurostimulation medical device company, announced today financial results for the fourth quarter and full year ended December 31, 2017.

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 0 Comments

Nexeon MedSystems to Host Shareholder Update November 20th, 2017

[fa icon="calendar"] November 16, 2017 - by : Company News

Company News

Nexeon MedSystems (OTCQB: NXNN) announced today a conference call to discuss 2017 results.  The call is scheduled for 4:00 p.m.  Central Standard Time on November 20th, 2017.   Analysts, investors, and other interested parties may access via conference line (https://www.uberconference.com/nexeon) or dialing an optional dial in number: 469-551-9824.  The call will also be archived on the Company investor relations page.

Topics: Conference Call

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 0 Comments

Nexeon Begins Clinical Study with Non-Invasive Vagus Nerve Stimulator

[fa icon="calendar"] October 25, 2017 - by : Company News

Company News

Feasibility Study for Treatment of Atrial Fibrillation is First Phase of €3.4M BioWin Award

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 3 Comments

Nexeon Awarded Research Grant to Develop Neurostim Therapy for Asthma

[fa icon="calendar"] October 19, 2017 - by : Company News

Company News

Nexeon MedSystems Inc (OTC:QB “NXNN”) announced today that it has received a Phase I Small Business Research Innovation (SBIR) grant from the National Heart, Lung and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), to develop a neurostimulation therapy for asthma in collaboration with researchers at Oregon Health Sciences University. The funding award was granted due to the merits of the proposed development plan for a novel asthma treatment related to airway constriction. This therapy would be a second-line defense for patients whose current medications do not adequately treat their asthma.

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 0 Comments

Nexeon MedSystems Begins Trading as NXNN

[fa icon="calendar"] September 28, 2017 - by : Company News

Company News

Dallas, TX -- Nexeon MedSystems, Inc. (OTC:QB NXNN) announced today that it has commenced "regular way" trading on the OTC Market (OTC:QB) under the symbol "NXNN".  The Company is finalizing development of its deep brain stimulation system for the treatment of symptoms associated with Parkinson's disease. 

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 0 Comments

Nexeon Medsystems "OTCQB:NXNN" Acquires Belgian Manufacturer

[fa icon="calendar"] September 6, 2017 - by : Company News

Company News

Additional capacity will support Company's current commercial product manufacturing needs 

Nexeon MedSystems ("Nexeon" or "the Company") (OTCQB: NXNN) announced today that it has exercised its option to acquire Nexeon Medsystems Belgium, SPRL ("NMB").  This Belgian-based company has been operating since 2013 developing neurostimulation products. NMB recently acquired Medi-Line, a Belgian medical device manufacturer with financing support provided by KBC and CBC Bank.  Medi-Line has expertise in active and non-active implants, and it has been profitable for its complete 25-year corporate history. For more information about the transaction, please review the Form 8-K.

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 0 Comments

Nexeon Names Daniel Powell Vice President of Sales and Marketing

[fa icon="calendar"] August 15, 2017 - by : Company News

Company News

Company Recruits Additional Deep Brain Stimulation Expertise in Preparation for European Product Launch

Dallas, TX – The Board of Directors of Nexeon MedSystems Inc (OTC:QB "NXNN") appointed Daniel Powell to serve as the Vice President, Sales and Marketing.  With over 20 years of experience working with advanced medical technology products, including 12 years in neuromodulation, management indicated that Powell’s onboarding has been swift.  He has taken on a position in the commercialization division at a critical time for the Company as it transitions from product development to product launch preparation.

Topics: Leadership

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 0 Comments

Nexeon Receives Research Grant from National Institutes of Health [Video]

[fa icon="calendar"] August 8, 2017 - by : Company News

Company News

Company spins out this program to focus on development of nanocomposite drug eluting balloon technology and other intellectual property related to precision medicine

Dallas, TX -- Nexeon MedSystems (OTCQB: “NXNN”) today announced that it has been awarded a two-year, Phase II Small Business Research Innovation (SBIR) grant from the National Heart, Lung and Blood Institute (NHLBI), part of the National Institutes of Health (NIH). The Company recently completed the Phase I FastTrack research plan associated with this proprietary system. The Phase II grant was awarded due to successful completion of corresponding Phase I milestones, and it will fund up to $600,000 of critical preclinical research and process development activities, including the completion of a pre-IDE meeting with the U.S. Food and Drug Administration.

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 0 Comments

Subscribe to Email Updates